FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells. حسب Franco A. Rossato (588513)

Resveratrol decreases CYP17A1 and CYP21A2 protein expression. حسب Nesa Marti (3851059)

"…<p>A. Gene expression profiling by qRT-PCR was performed for CYP17, CYP21 and their cofactor POR in H295R cells grown under normal conditions (GM), starvation conditions (SM), metformin (Met) (1mM) treatment and under resveratrol (RSV) (5<u>μM)</u> treatment. …"

BMP type I receptor antagonists decrease Smad 1/5/8 activity in H1299 cells. حسب Elaine Langenfeld (402034)

Correlates of osteogenic differentiation. حسب Fabian Westhauser (5314436)

Knockdown of factors in the 5′SS recognition complex U1 globally decreases intronic miRNA levels. حسب Maja M. Janas (200408)

CD5-2 decreases established CCM lesions in the hindbrain of <i>Ccm2</i>^<i>ECKO</i> mice and lesions in the retina of <i>Ccm2</i>^<i>ECKO</i> mice. حسب Jia Li (160557)

D-4F and L-5F decrease hepatic mRNA level of genes involved in gluconeogenesis. حسب Kristine C. McGrath (8269155)

D-4F and L-5F decrease hepatic mRNA levels of genes involved in lipogenesis. حسب Kristine C. McGrath (8269155)

Chronic exposure of human PAC to nicotine decreases carrier-mediated [³H] thiamin uptake. حسب Padmanabhan Srinivasan (481324)

Lithium Decreases Glial Fibrillary Acidic Protein in a Mouse Model of Alexander Disease حسب Christine M. LaPash Daniels (796881)

"…Here we tested whether lithium treatment would decrease levels of GFAP in a mouse model of Alexander disease. …"

Decreasing RhoB expression by siRNA transfection does not change Ad5wt attachment or internalization. حسب Dragomira Majhen (462312)

Oleic acid treatment decreases MDA formation, and induces UCP2 and AMPK in septic mice. حسب Cassiano Felippe Gonçalves-de-Albuquerque (846954)

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات: